Novo Nordisk (NVO) rated Buy as oral Wegovy lifts GLP-1 sales, expands obesity market and boosts 2026 guidance. Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVO either t...
Analysts are debating what has caused crypto to underperform in 2025 despite favorable conditions, with the total market cap down 32% from its high. Analysts and investors are questioning why crypto i...
